Regulating Splice Efficiency: The Role of ARVCF in Disease (G421)

Target Name: ARVCF

NCBI ID: G421

ARVCF

Other Name(s): Splicing regulator ARVCF | ARVC_HUMAN | Armadillo repeat protein deleted in velo-cardio-facial syndrome | Armadillo repeat protein | Splicing regulator ARVCF; armadillo repeat protein deleted in velo-cardio-facial syndrome | ARVCF delta catenin family member | Armadillo repeat protein deleted in velo-cardio-facial syndrome isoform X2 | armadillo repeat gene deleted in velocardiofacial syndrome

Regulating Splice Efficiency: The Role of ARVCF in Disease

splice modifier proteins, also known as splicing factors, are a class of proteins that play a critical role in regulating gene expression during the process of splicing. One of the well-known splicing factors is the ARVCF (AR-associated variable capital-f) , which is a protein that is expressed in various tissues and cells and is involved in the regulation of splicing efficiency.

ARVCF is a member of the AR-associated protein family, which includes a variety of proteins that are involved in the regulation of splicing. These proteins are characterized by the presence of an RNA-binding domain and a catalytic domain, which allows them to interact with RNA molecules and catalyze the splicing process.

One of the unique features of ARVCF is its ability to regulate splicing efficiency in different cell types and tissues. For example, studies have shown that ARVCF is highly expressed in the brain and that it plays a critical role in regulating the accuracy of gene expression in this tissue. Additionally, ARVCF has been shown to be involved in the regulation of splicing in various diseases, including cancer.

The splice regulation is a complex process that involves the coordination of multiple factors, including splicing factors, the 3' end of the pre-mRNA, and the 5' end of the intron. ARVCF is involved in the regulation of several key steps in this process, including the formation of the splicing complex, the recognition of the 3' end of the pre-mRNA, and the cleavage of the intron.

One of the key functions of ARVCF is its ability to recognize the 3' end of the pre-mRNA and recruit splicing factors to this region. This recognition process is critical for ensuring that the correct splicing factors are recruited to the site and that the splicing factors complex is formed. ARVCF has been shown to interact with several splicing factors, including SF3B, which is a well-known splicing factor that is involved in the regulation of splicing efficiency.

In addition to its role in recognizing the 3' end of the pre-mRNA, ARVCF is also involved in the regulation of the 5' end of the intron. This is accomplished through its ability to recognize and cleave specific sequences at the intron-5 ' end. This cleavage is necessary for the separation of the introns from the exons during splicing.

ARVCF has also been shown to be involved in the regulation of splicing efficiency in various diseases. For example, studies have shown that ARVCF is highly expressed in various types of cancer, including breast, lung, and colorectal cancer. Additionally, studies have shown that ARVCF is involved in the regulation of splicing efficiency in diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In conclusion, ARVCF is a protein that is involved in the regulation of splicing efficiency and has been shown to be involved in various diseases. Its role in this process is complex and involves the coordination of multiple factors, including splicing factors, the 3' end of the pre-mRNA, and the 5' end of the intron. Further research is needed to fully understand the mechanisms of ARVCF and its role in the regulation of splicing efficiency.

Protein Name: ARVCF Delta Catenin Family Member

Functions: Contributes to the regulation of alternative splicing of pre-mRNAs

The "ARVCF Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARVCF comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets